Legacy Financial Advisors, Inc. Nektar Therapeutics Transaction History

Legacy Financial Advisors, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 16, 2019	SELL	$30.43 - $56.65 $5,294 - $9,857	-174 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$46.25 - $104.45 $3,931 - $8,878	85 Added 95.51%	174 $8,000
Q1 2018 Apr 12, 2018	BUY	$57.4 - $108.44 $5,108 - $9,651	89 New	89 $9,000

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Legacy Financial Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Legacy Financial Advisors, Inc. with notifications on news.